JAK inhibitors and other novel agents in myeloproliferative neoplasms: Are we hitting the target?

Therapeutic Advances in Hematology

Volumn 2, Issue 4, 2011, Pages 203-211

  Kucine, Nicole ^a   Levine, Ross L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

essential thrombocytosis; JAK inhibitor; JAK kinases; myelofibrosis; myeloproliferative disorder; polycythemia vera

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ARSENIC TRIOXIDE; BEVACIZUMAB; DASATINIB; DEHYDRODIDEMNIN B; ENTINOSTAT; ERLOTINIB; GANDOTINIB; GANETESPIB; GIVINOSTAT; HYDROXYUREA; IMATINIB; IPI 493; JANUS KINASE INHIBITOR; LESTAURTINIB; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; RUXOLITINIB; SNX 5422; TAK 901; UNCLASSIFIED DRUG; VORINOSTAT;

ANEMIA; CANCER INHIBITION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROLEUKEMIA; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; LEUKOCYTOSIS; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPLEEN SIZE; SPLEEN WEIGHT; SPLENOMEGALY; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84993813067     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620711410095     Document Type: Review

References (44)

1. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054–1061.
2. Besses C. Cervantes F. Pereira A. Florensa L. Sole F. Hernandez-Boluda J.C. et al (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 13: 150–154.
3. Dameshek W. (1951) Some speculations on the myeloproliferative syndromes. Blood 6: 372–375.
4. Deeg H.J. Gooley T.A. Flowers M.E. Sale G.E. Slattery J.T. Anasetti C. et al (2003) Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102: 3912–3918.
5. Druker B.J. Sawyers C.L. Kantarjian H. Resta D.J. Reese S.F. Ford J.M. et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–1042.
6. Grana A. Marchiolo B. (1967) [Contribution to the study of the clearance of I-131 in skin grafts]. Minerva Dermatol 42: 83–85.
7. Guerini V. Barbui V. Spinelli O. Salvi A. Dellacasa C. Carobbio A. et al (2008) The histone deacetylase inhibitor ITF 2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 22: 740–747.
8. Harrison C.N. Campbell P.J. Buck G. Wheatley K. East C.L. Bareford D. et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353: 33–45.
9. Hedvat M. Huszar D. Herrmann A. Gozgit J.M. Schroeder A. Sheehy A. et al (2009) The JAK2 inhibitor AZD 1480 potently blocks Stat 3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487–497.
10. Hexner E.O. Serdikoff C. Jan M. Swider C.R. Robinson C. Yang S. et al (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663–5671.
11. James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144–1148.
12. Kiladjian J.J. Cassinat B. Chevret S. Tourlure P. Cambier N. Roussel M. et al (2008) Pegylated interferon alpha-2a induces complete hematological and molecular responses with low toxicity in polycythemia vera. Blood in press.
13. Kralovics R. Passamonti F. Buser A.S. Teo S.S. Tiedt R. Passweg J.R. et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790.
14. Larsen T.S. Pallisgaard N. de Stricker K. Moller M.B. Hasselbalch H.C. (2009) Limited efficacy of hydroxyurea in lowering of the JAK2V617F allele burden. Hematology 14: 11–15.
15. Lasho T.L. Pardanani A. Tefferi A. (2010) LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 363: 1189–1190.
16. Lasho T.L. Tefferi A. Hood J.D. Verstovsek S. Gilliland D.G. Pardanani A. (2008) TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 22: 1790–1792.
17. Levine R.L. Gilliland D.G. (2008) Myeloproliferative disorders. Blood 112: 2190–2198.
18. Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387–397.
19. Lucet I.S. Fantino E. Styles M. Bamert R. Patel O. Broughton S.E. et al (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107: 176–183.
20. Marchioli R. Finazzi G. Landolfi R. Kutti J. Gisslinger H. Patrono C. et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23: 2224–2232.
21. Marubayashi S. Koppikar P. Taldone T. Abdel-Wahab O. West N. Bhagwat N. et al (2010) HSP 90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 120: 3578–3593.
22. Mullally A. Lane S.W. Ball B. Megerdichian C. Okabe R. Al-Shahrour F. et al (2010) Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17: 584–596.
23. Pardanani A. Brown P. Neben-Wittich M. Tobin R. Tefferi A. (2010 a) Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. Am J Hematol 85: 715–716.
24. Pardanani A. George G. Lasho T. Hogan W.J. Litzow M.R. Begna K. et al (2010 b) A phase I / II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood 116 abstract 460.
25. Pardanani A. Gotleib J. Jamieson C. Cortes J. Talpaz M. Stone R. et al (2009 a) A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood - American Society of Hematology Annual Meeting in press.
26. Pardanani A. Gotlib J.R. Jamieson C. Cortes J.E. Talpaz M. Stone R.M. et al (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol in press.
27. Pardanani A. Lasho T. Smith G. Burns C.J. Fantino E. Tefferi A. (2009 b) CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 23: 1441–1445.
28. Pardanani A. Vannucchi A.M. Passamonti F. Cervantes F. Barbui T. Tefferi A. (2010 c) JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia in press.
29. Pardanani A.D. Levine R.L. Lasho T. Pikman Y. Mesa R.A. Wadleigh M. et al (2006) MPL 515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108: 3472–3476.
30. Pearson T.C. Wetherley-Mein G. (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 2: 1219–1222.
31. Pietra D. Li S. Brisci A. Passamonti F. Rumi E. Theocharides A. et al (2008) Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111: 1686–1689.
32. Pikman Y. Lee B.H. Mercher T. McDowell E. Ebert B.L. Gozo M. et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270–e270.
33. Quintas-Cardama A. Kantarjian H. Manshouri T. Luthra R. Estrov Z. Pierce S. et al (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27: 5418–5424.
34. Quintas-Cardama A. Vaddi K. Liu P. Manshouri T. Li J. Scherle P.A. et al (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 3109–3117.
35. Ramakrishnan V. Kimlinger T. Haug J. Timm M. Wellik L. Halling T. et al (2010) TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol 85: 675–686.
36. Ruggeri M. Finazzi G. Tosetto A. Riva S. Rodeghiero F. Barbui T. (1998) No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 103: 772–777.
37. Santos F.P. Kantarjian H.M. Jain N. Manshouri T. Thomas D.A. Garcia-Manero G. et al (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera / essential thrombocythemia myelofibrosis. Blood 115: 1131–1136.
38. Schoof N. von Bonin F. Trumper L. Kube D. (2009) HSP 90 is essential for JAK–STAT signaling in classical Hodgkin lymphoma cells. Cell Commun Signal 7: 17–18.
39. Scott L.M. Tong W. Levine R.L. Scott M.A. Beer P.A. Stratton M.R. et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459–468.
40. Shang L. Tomasi T.B. (2006) The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons. J Biol Chem 281: 1876–1884.
41. Tyner J.W. Bumm T.G. Deininger J. Wood L. Aichberger K.J. Loriaux M.M. et al (2010) CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115: 5232–5240.
42. Verstovsek S. Kantarjian H. Mesa R.A. Pardanani A.D. Cortes-Franco J. Thomas D.A. et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117–1127.
43. Wanner S.P. Guimaraes J.B. Pires W. La Guardia R.B. Haibara A.S. Marubayashi U. et al (2010) Physical exercise-induced cardiovascular adjustments are modulated by muscarinic cholinoceptors within the ventromedial hypothalamic nucleus. Physiol Res 59: 165–175.
44. Wernig G. Kharas M.G. Okabe R. Moore S.A. Leeman D.S. Cullen D.E. et al (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13: 311–320.